Abnormalities, Multiple: Clinical Trials

79 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

79 completed. 79 Phase 1, 24 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 179Completed 79
Phase 224Completed 24

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 79 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
VX-407, LNG/EE, NGM/EE - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1CompletedVertex Pharmaceuticals Incorporated742025-07-112026-03-30
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
VX-407, Placebo - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1CompletedVertex Pharmaceuticals Incorporated322025-06-122026-03-27
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
RCT1100 - Primary Ciliary Dyskinesia (PCD)
Phase 1CompletedReCode Therapeutics142024-10-222026-04-30
A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD
RCT1100 - Primary Ciliary Dyskinesia
Phase 1CompletedReCode Therapeutics72024-09-202025-10-08
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
ATR12-351 - Netherton Syndrome
Phase 1CompletedAzitra Inc.62024-06-162026-07-29
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
VX-407, Placebo, Midazolam - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1CompletedVertex Pharmaceuticals Incorporated1592024-04-172025-07-14
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Leucettinib-21 - Healthy Volunteers, Down Syndrome
Phase 1CompletedPerha Pharmaceuticals1522024-01-182026-06-30
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC
KM-001 cream 1% 12 weeks treatment., Physical Examination, Vital Signs - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita
Phase 1CompletedOrvida Pharma (formerly Kamari Pharma)182023-03-062025-01-15
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
RCT1100 - Primary Ciliary Dyskinesia
Phase 1CompletedReCode Therapeutics92023-02-182025-04-29
Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
Placebo, AEF0217 - Down Syndrome
Phase 1 / Phase 2CompletedAelis Farma402022-12-152024-10-10
A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
CSTI-500 - Prader-Willi Syndrome
Phase 1CompletedConSynance Therapeutics102022-11-142023-08-09
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
DS-2325a, Placebo - Netherton Syndrome
Phase 1CompletedDaiichi Sankyo242022-11-082023-05-18
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
RGLS8429, Placebo - Autosomal Dominant Polycystic Kidney Disease, ADPKD
Phase 1CompletedRegulus Therapeutics Inc.682022-10-062025-06-03
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases
Serum chemistry, Hematology, Urinalysis - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita
Phase 1CompletedOrvida Pharma (formerly Kamari Pharma)142022-07-172025-01-07
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
DS-2325a, Placebo - Netherton Syndrome
Phase 1CompletedDaiichi Sankyo642022-06-202023-03-06
A Study of RGLS8429 in Healthy Volunteers
RGLS8429, Placebo volume-matching RGLS8429 dose - Healthy Volunteers
Phase 1CompletedRegulus Therapeutics Inc.322022-06-102025-08-27
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
SXR1096 cream, Placebo cream - Netherton Syndrome
Phase 1 / Phase 2CompletedSixera Pharma92021-12-072025-12-16
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
AZD5055, Placebo - Idiopathic Pulmonary Fibrosis
Phase 1CompletedAstraZeneca632021-11-182024-05-16
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
AL01211 or Placebo (Part A), AL01211 or Placebo (Part B) - Autosomal Dominant Polycystic Kidney
Phase 1CompletedAceLink Therapeutics, Inc.692021-06-082022-10-14
A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
RO7248824 - Angelman Syndrome
Phase 1CompletedHoffmann-La Roche212021-04-292022-09-08

Showing 20 of 79. Sign in to see all of them.

Narrower conditions

Down Syndrome (11)  ·  Polycystic Kidney, Autosomal Dominant (11)  ·  Prader-Willi Syndrome (9)  ·  Angelman Syndrome (6)  ·  Netherton Syndrome (6)  ·  Pachyonychia Congenita (5)  ·  von Hippel-Lindau Disease (5)  ·  Basal Cell Nevus Syndrome (4)  ·  DiGeorge Syndrome (4)  ·  Autism Spectrum Disorder (3)  ·  Autistic Disorder (3)  ·  Carcinoma, Basal Cell (3)  ·  Ciliary Motility Disorders (3)  ·  Intellectual Disability (3)  ·  Kartagener Syndrome (3)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (79)  ·  Congenital Abnormalities (78)  ·  Genetic Diseases, Inborn (76)  ·  Nervous System Diseases (37)  ·  Chromosome Disorders (31)  ·  Neurologic Manifestations (26)  ·  Neurobehavioral Manifestations (22)  ·  Ciliopathies (21)  ·  Intellectual Disability (19)  ·  Imprinting Disorders (15)  ·  Nutritional and Metabolic Diseases (15)  ·  Skin and Connective Tissue Diseases (15)  ·  Cardiovascular Diseases (14)  ·  Female Urogenital Diseases (14)

Interventions

Oxytocin (4)  ·  Ranibizumab (3)  ·  Hematologic Tests (2)  ·  Pain Measurement (2)  ·  Physical Examination (2)  ·  Sirolimus (2)  ·  Sodium Chloride (2)  ·  Therapeutics (2)  ·  Thymus Extracts (2)  ·  Urinalysis (2)  ·  Vital Signs (2)  ·  XL647 (2)  ·  1-phenyl-3,3-dimethyltriazene (1)  ·  Antilymphocyte Serum (1)  ·  Biopsy (1)

Sponsors

Hoffmann-La Roche (4)  ·  National Eye Institute (NEI) (3)  ·  ReCode Therapeutics (3)  ·  Regulus Therapeutics Inc. (3)  ·  Sumitomo Pharma Switzerland GmbH (3)  ·  Vertex Pharmaceuticals Incorporated (3)  ·  Albireo (2)  ·  Boston Children's Hospital (2)  ·  Daiichi Sankyo (2)  ·  National Human Genome Research Institute (NHGRI) (2)  ·  Orvida Pharma (formerly Kamari Pharma) (2)  ·  University Hospital, Toulouse (2)  ·  University of Florida (2)  ·  AC Immune SA (1)  ·  AceLink Therapeutics, Inc. (1)

Countries

United States (58)  ·  United Kingdom (8)  ·  France (6)  ·  Australia (5)  ·  Canada (4)  ·  Netherlands (4)  ·  Germany (3)  ·  Spain (3)  ·  Israel (2)  ·  Austria (1)  ·  Denmark (1)  ·  Iran (1)  ·  Italy (1)  ·  New Zealand (1)  ·  Sweden (1)

Top investigators

John Matthews, MBBS, MCRP, PhD (3)  ·  M. Louise Markert, MD, PhD (3)  ·  Rekha Garg, MD (2)  ·  Albert C Yan, MD (1)  ·  Alexander C Conley, PhD (1)  ·  Allen E. Bale, MD (1)  ·  Atieh Makhlough, MD (1)  ·  Bernard Cohen, MD (1)  ·  Bill Grobman, M.D., M.B.A (1)  ·  Edward Neilan, MD (1)  ·  Edward V. Maytin, MD, PhD (1)

Results publications

PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 39356039, PMID 15100156, PMID 17284531, PMID 23607606, PMID 14605787, PMID 14662594, PMID 15100681, PMID 18155964, PMID 18333898, PMID 20083693, PMID 20978268, PMID 22590644, PMID 28100688, PMID 28535817, PMID 28823614, PMID 30803705, PMID 31215818, PMID 32077057, PMID 33232306, PMID 34185708, PMID 34549489, PMID 34649967, PMID 35532913, PMID 35690720, PMID 36947593, PMID 37018064, PMID 37120522, PMID 37418643, PMID 39331470, PMID 40646322, PMID 41348481, PMID 41385299, PMID 41643210, PMID 41701531, PMID 8209913, PMID 9024564, PMID 9024565

NIH funding

K12HD043494 (3), R01AI047040 (3), R01AI054843 (3), R56AI047040 (2), 2016 (1), 2018 (1), 2019 (1), 2023 (1), R01AG047922 (1), R21DK113487 (1)